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ARTICLE
Anti-human TREM2 induces microglia proliferation
and reduces pathology in an Alzheimer’s disease
model
Shoutang Wang1*, Meer Mustafa2*, Carla M. Yuede3, Santiago Viveros Salazar2, Philip Kong2, Hua Long2, Michael Ward2, Omer Siddiqui2,
Robert Paul2, Susan Gilfillan1, Adiljan Ibrahim2, Hervé Rhinn2, Ilaria Tassi2, Arnon Rosenthal2, Tina Schwabe2, and Marco Colonna1
TREM2 is a receptor for lipids expressed in microglia. The R47H variant of human TREM2 impairs ligand binding and increases
Alzheimer’s disease (AD) risk. In mouse models of amyloid β (Aβ) accumulation, defective TREM2 function affects microglial
response to Aβ plaques, exacerbating tissue damage, whereas TREM2 overexpression attenuates pathology. Thus, AD may
benefit from TREM2 activation. Here, we examined the impact of an anti-human TREM2 agonistic mAb, AL002c, in a mouse AD
model expressing either the common variant (CV) or the R47H variant of TREM2. Single-cell RNA-seq of microglia after acute
systemic administration of AL002c showed induction of proliferation in both CV- and R47H-transgenic mice. Prolonged
administration of AL002c reduced filamentous plaques and neurite dystrophy, impacted behavior, and tempered microglial
inflammatory response. We further showed that a variant of AL002c is safe and well tolerated in a first-in-human phase I
clinical trial and engages TREM2 based on cerebrospinal fluid biomarkers. We conclude that AL002 is a promising candidate
for AD therapy.
Introduction
Alzheimer’s disease (AD) is the most common form of senile
dementia. It affects one in eight Americans over the age of 65 yr
and is the sixth leading cause of death in the United States
(https://www.alz.org/alzheimers-dementia/facts-figures). AD
is characterized by memory and executive function deficits,
followed by progressive, global cognitive decline (Long and
Holtzman, 2019; Sarlus and Heneka, 2017). Brain AD pathology
consists of extracellular aggregates of amyloid β (Aβ) oligomers
and large insoluble plaques, intraneuronal tau hyper-
phosphorylation, synaptic dysfunction, and neuronal cell death
(Long and Holtzman, 2019; Sarlus and Heneka, 2017). AD le-
sions trigger a secondary expansion of reactive microglia,
which cluster around Aβ plaques, limiting their spreading
(Long and Holtzman, 2019; Sarlus and Heneka, 2017). Profiling
of microglia transcriptome in mouse models of Aβ accumula-
tion has revealed that this increase in microglia numbers is
associated with a robust transcriptional activation signature on
a per-microglia basis, which has been referred to as disease-
associated microglia (DAM), which is quite distinct from that
of homeostatic microglia (Keren-Shaul et al., 2017). Recently,
the analysis of the human microglial transcriptome in AD by
single-nucleus RNA sequencing (RNA-seq) has revealed a mi-
croglial transcriptional response that in part recapitulates the
mouse DAM signature (Mathys et al., 2019; Zhou et al., 2020).
Studies of genetic risk for sporadic AD have suggested that
microglia not only respond to disease but also modulate disease
course (Karch and Goate, 2015; Lambert et al., 2013). Most no-
tably, a hypomorphic missense mutation in the microglia re-
ceptor TREM2, R47H, increases the risk of AD severalfold, as do
other TREM2 variants, such as R62H, although with reduced
penetrance (Jonsson et al., 2013; Guerreiro et al., 2013). TREM2
is a lipid receptor expressed in microglia and other tissue mac-
rophages, which promotes their survival and proliferation by
transmitting intracellular activating signals through the adaptor
DAP12. Impaired TREM2 function in the 5XFAD mouse model of
Aβ pathology restricts the ability of microglia to proliferate and
accumulate around Aβ plaques to limit their pathogenic poten-
tial (Wang et al., 2015). TREM2-deficient microglia can acquire
an incomplete DAM profile, or stage 1 DAM, but fail to develop a
completely activated profile, or stage 2 DAM (Keren-Shaul et al.,
2017). This defective microglial response leads to greater neu-
ritic dystrophy adjacent to Aβ plaques (Yuan et al., 2016; Wang
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et al., 2016). The beneficial role of TREM2-dependent microglial
activation has been further supported by an in vivo study
showing that 5XFAD mice develop less Aβ pathology when
crossed to transgenic (Tg) mice overexpressing human TREM2
(hTREM2; Lee et al., 2018). Moreover, a recent study showed
that myeloid cells with potentially beneficial effects on neuro-
degeneration can be generated in vitro with an agonist TREM2
antibody (Cheng et al., 2018). Taken together, these findings
suggest that TREM2-dependent microglial activation can delay
AD onset and/or progression.
In this study, we examined the potential therapeutic impact
of a mouse anti-hTREM2 agonistic mAb named AL002c, which
is a variant of a mAb, called AL002, that has recently been
studied in a phase I clinical trial (https://clinicaltrials.gov/ct2/
show/NCT03635047). The antibody was tested in Tg mice that
express either the common variant (CV) or the R47H variant of
hTREM2, but lack the endogenous Trem2 gene (referred to as CV
knockout [CV-KO] and R47H-KO, respectively; Song et al., 2018).
We had previously shown that 5XFAD mice crossed to CV-KO
(CV-KO-5XFAD) show more microglia activation and plaque
coverage than 5XFADmice crossed to R47H-KOmice (R47H-KO-
5XFAD). We found that a single injection of AL002c expanded
unique subpopulations of metabolically active and proliferating
microglia in both CV-KO-5XFAD and R47H-KO-5XFAD mice, as
assessed by single-cell RNA-seq (scRNA-seq). Moreover, pro-
longed treatment of both mouse models with AL002c curtailed
the formation of filamentous neurotoxic plaques, as well as the
extent of neurite dystrophy, and improved behavior. Attenuated
pathology was associated with reduced activation of microglia in
response to Aβ plaques, as indicated by diminished clustering
around plaques and reduced expression of the inflammation
marker SPP1. Finally, we showed that the AL002 version of
AL002c can be given safely in a first-in-human phase I clinical
trial and identified soluble TREM2 (sTREM2) and soluble CSF-1R
(sCSF-1R) as biomarkers indicative of TREM2 engagement in
humans. We conclude that antibody-mediated activation of
TREM2 in microglia can provide a potential avenue of thera-
peutic intervention capable of attenuating the neurotoxic impact
of Aβ pathology.
Results
AL002c activates hTREM2 in vitro and in vivo
AL002c is a mouse IgG1 anti-hTREM2 mAb that was generated
using the recombinant hTREM2 extracellular domain as an
immunogen in a hybridoma approach, followed by humaniza-
tion and affinity maturation by yeast display. In most experi-
ments, we used AL002c with the intact Fc region, as mouse IgG1
has poor effector functions (Bruhns and Jönsson, 2015) and
therefore is unlikely to markedly impact the behavior of the
antibody. To validate the specificity of AL002c, we stained bone
marrow–derived macrophages (BMMs) prepared from CV- and
R47H-KO mice. We corroborated that AL002c binds hTREM2
and demonstrated that binding is not affected by the R47H
mutation (Fig. 1 A). We further established by peptide epitope
mapping that AL002c binds a region of the extracellular domain
of TREM2 spanning amino acids 112–174 (not depicted).
To see whether AL002c activates hTREM2, we next tested
the Ca2+-driven reporter cell line 2B4 stably transfected with
either hTREM2 CV or R47H together with DAP12 (Fig. S1 A; Song
et al., 2017). In these reporter cells, engagement of hTREM2
promotes Ca2+ signals that lead to nuclear translocation of NFAT
and NFAT-driven synthesis of enhanced GFP (EGFP), which is
detected by flow cytometry. AL002c induced EGFP in both CV
and R47H reporter cells, while a control IgG did not, suggesting
that AL002c acts as an hTREM2 agonist (Fig. 1 B). Similar results
were obtained with another CV-expressing Ca2+-driven reporter
cell in which Ca2+ signals induce luciferase rather than EGFP
(Fig. S1 B).
Previously, we demonstrated that TREM2 cooperates with
CSF-1R, sustaining in vitro survival of BMMs after CSF-1 with-
drawal (Otero et al., 2009; Wang et al., 2015; Ulland et al., 2017).
We also showed that hTREM2 CV sustains macrophage viability
more effectively than hTREM2 R47H (Song et al., 2018). Thus,
we tested whether AL002c impacts in vitro survival of macro-
phages after CSF-1 withdrawal. Human monocyte-derived mac-
rophages treated with AL002c were more viable than those
treated with control IgG after 48 h of CSF-1 withdrawal, as-
measured by an ATP level–based viability assay (Fig. 1 C). In-
terestingly, mutations of the Fc region of AL002c that block
binding to Fc receptors and complement (also known as
LALAPS) only slightly quelled its prosurvival effect on myeloid
cells (Fig. S1 C), suggesting that AL002c-mediated activation of
hTREM2 function is largely independent of mAb-mediated
cross-linking of Fc receptors. Finally, AL002c but not control
IgG sustained cell viability of BMM derived from CV-KO and
R47H-KO mice (Fig. 1 D), demonstrating that AL002c activates
both hTREM2 variants.
To further corroborate that AL002c is an agonistic antibody,
we assessed its capacity to activate DAP12 signaling in macro-
phages. In a first set of experiments, we generated BMM from
CV-KO and R47H-KO mice and stimulated them in vitro with
two different doses of AL002c or a control IgG, followed
by immunoprecipitation with a distinct anti-TREM2 anti-
body. Analysis of the immunoprecipitates with an anti-
phosphotyrosine antibody showed that AL002c induced
phosphorylation of a protein with a molecular weight cor-
responding to DAP12, whereas the control IgG did not (Fig. 1
E). Anti-DAP12 immunoblot confirmed that TREM2 associ-
ates with DAP12 regardless of phosphorylation.
We conducted two additional sets of experiments using an-
other Tg mouse that expresses both hTREM2 CV and endoge-
nous mouse Trem2 (referred to as hTREM2-Bac-Tg). First, we
demonstrated that AL002c induced DAP12 phosphorylation in
BMM prepared from hTREM2-Bac-Tg but not in BMM fromWT
non-Tg B6 mice (Fig. S1 D), corroborating that AL002c selec-
tively activates hTREM2 but not mouse Trem2 signaling. Sec-
ond, we investigated whether AL002c activates DAP12 signaling
in vivo in peritoneal macrophages elicited by i.p. injection
of thioglycolate. After induction of peritoneal macrophages
in hTREM2-Bac-Tg and WT mice, AL002c or a control IgG
were directly injected in the peritoneal cavity to stimulate
macrophages in vivo. Peritoneal cells were recovered, lysed,
and analyzed by immunoprecipitation with anti-TREM2 and
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immunoblotting with anti-phosphotyrosine. AL002c but not
control IgG induced DAP12 phosphorylation in peritoneal mac-
rophages from hTREM2-Bac-Tg mice (Fig. S1 E). Altogether,
these results demonstrate that AL002c functions as a TREM2
agonist for both hTREM2 CV and R47H in vitro and in vivo.
Systemically administered AL002 can cross the blood–brain
barrier and attain concentrations that activate TREM2
To design a dosing regimen that ensures therapeutic efficacy in
the 5XFAD model, we performed a pharmacokinetic study. This
determination was important, because peripherally adminis-
teredmAbs cross the blood–brain barrier poorly, and hencemAb
concentration is expected to be much lower in the brain than in
plasma. For this experiment, we used the clinical variant of
AL002c, called AL002, which is on a human IgG1 backbone,
facilitating detection in mouse brain lysates and plasma using
anti-human IgG. We chose i.p. injection as a route of adminis-
tration. A single dose of AL002 was administered i.p. at 5, 20,
and 60 mg/kg into hTREM2-Bac-Tg mice on day 0 (Fig. S2 A).
Plasma and brain homogenate samples were collected for mea-
surement of antibody levels from cohorts of mice on days 1, 2, 4,
8, 14, and 21. The concentration of human IgG in the brain was
∼0.11% of that in plasma at all time points in all mice (Fig. S2, B
and C). The terminal half-life in hTREM2-Bac-Tg mice was rel-
atively short, ranging from 1 to 1.8 d (Fig. S2, D and E). Given that
hTREM2 is overexpressed in these mice, the short half-life may
be due to enhanced target-mediated disposition in this model.
Using the viability assay described in Fig. 1 C, we also de-
termined the concentration of AL002 that confers half-maximal
viability (EC50) of monocyte-derived macrophages in vitro (Fig.
S2 F). By this approach, we found that the EC50 for AL002 is
between 0.36 and 0.47 nM. Furthermore, comparison of AL002
concentrations in the brain with the calculated EC50 indicated
that the concentration of AL002 in the brain is above the EC50 at
all three doses on day 2 after administration. Therefore, we
chose a dose of 30 mg/kg for subsequent in vivo experiments.
Figure 1. AL002c is a TREM2 agonist. (A) CV- and R47H-derived BMM were cultured for 7 d, harvested, and stained with AL002c (black solid line his-
tograms) or isotype control (gray histograms). This experiment is representative of three independent experiments. (B) 2B4 reporter cell lines expressing
hTREM2 CV or hTREM2 R47Hwere stimulated with grading doses of control IgG or AL002c in solution. EGFP expression wasmeasured by flow cytometry. Data
are representative of two independent experiments as mean ± SEM. (C) Human macrophages were cultured for 7 d and stimulated for 48 h with grading doses
of IgG or AL002c in solution. Viability was measured by CellTiter Glow. Data are representative of 10 independent experiments as mean ± SD. (D) BMM derived
from CV-KO and R47H-KO were cultured for 7 d and stimulated for 96 h with grading doses of IgG or AL002c in solution. Viability was measured by CellTiter
Glow. ***, P < 0.001 by two-way ANOVA. Data are presented as mean ± SEM. (E) BMM derived from CV-KO and R47H-KO were stimulated for 15 min with two
different concentrations of control IgG or AL002c. Cells were then lysed, immunoprecipitated (IP) with a distinct anti-TREM2 antibody, blotted with anti-
phosphotyrosine antibody, stripped, and blotted with anti-DAP12 antibody. For control loading, whole-cell lysates were blotted with anti-actin antibody.
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AL002c drives metabolic activation and proliferation of
microglia in vivo
To characterize the impact of AL002c on microglial activation
in vivo, we performed scRNA-seq. CV-KO-5XFAD and R47H-KO-
5XFAD mice were injected with either AL002c or isotype con-
trol. After 48 h, Cd45+ cells were isolated fromwhole brains, and
RNA transcripts from single cells were barcoded, reverse tran-
scribed, and sequenced using the 10X Genomics platform (Fig. 2
A). Most cells had similar numbers of unique molecular identi-
fiers (UMIs), or distinct RNA molecules (not depicted). A total of
42,409 single cells were plotted on uniform manifold approxi-
mation projection (UMAP) dimensions for visualization. Unsu-
pervised clustering revealed a total of 12 broad cell types
comprising 20 distinct clusters across all mice (Fig. S3 A). These
clusters were annotated based on differential expression of
known cell type–specific marker genes (Fig. S3 B). The pre-
ponderance of cells captured by our scRNA-seq dataset were
microglia (clusters 0, 1, 2, 3, 4, 8, 15, and 17; ∼75% of all Cd45+
cells), with significantly lower numbers of border-associated
macrophages (BAMs; clusters 5 and 18), T cells (clusters 6 and
14), B cells (clusters 9 and 19), neutrophils (clusters 10 and 11),
natural killer cells (cluster 13), monocytes (cluster 12), S-phase
cells (cluster 16), and proliferating G2-/M-phase cells (cluster 7;
Fig. S3 B). Compared with control IgG, AL002c did not have a
significant impact on any of the clusters representing non-
microglial cell types.
Taking advantage of the single-cell resolution of our data, we
reclustered 31,948 microglia cells into 12 clusters (Fig. 2, B and
C). Based on expression of published microglia subtype-specific
marker genes (Sala Frigerio et al., 2019; Keren-Shaul et al., 2017;
Mathys et al., 2017), we identified homeostatic microglia (clus-
ters 0, 1, 2, 4, and 5; HM1-5), stage 1 DAM (cluster 8; DAM1),
stage 2 DAM (cluster 3; DAM2), and microglia with intermediate
features between homeostatic and DAM, which we define as
transitioning microglia (cluster 7; Fig. 2, D and E; and Fig. 3 A).
We further identified three clusters of proliferating microglia in
the G2/M phase (clusters 9 and 11; PM1-2) and S-phase (cluster
10; SM), as well as one cluster expressing IFN-induced genes,
which we define as IFN-response microglia (cluster 6; Fig. 2, D
and E; and Fig. 3 A). There was a residual cluster of non-
microglial cells carried over in this analysis, which was removed
and no longer considered in subsequent analyses.
We next compared the microglia clusters obtained frommice
in each experimental category (Fig. 3, B–E). Microglia repre-
sented >70% of the Cd45+ cells from all mice analyzed compared
with other myeloid and lymphocytic cells (Fig. 3 B). More mi-
croglia in clusters 7 (transitioning) and 9 (G2/M phase) were
present frommice injectedwith AL002c than frommice injected
with the control antibody (Fig. 3, C–E), whereas fewer microglia
were present in cluster 1 (homeostatic). These results suggested
that injection of AL002c expands microglia transitioning from
homeostatic to DAM and proliferating microglia, at the expense
of homeostatic microglia.
Further examination of clusters 7 and 9 corroborated that
they were significantly enriched in AL002c-treated mice (Fig. 4,
A and B). Interestingly, microglia were more activated and
proliferative in response to AL002c in R47H mice than CV mice.
We speculate that microglia expressing CV are already activated
by endogenous ligands in the steady state and hence are less
responsive to AL002c. Analysis of differentially expressed genes
(DEGs) in clusters 7 and 1 (homeostatic microglia) showed that
cluster 7 was enriched for genes encoding ribosomal proteins,
indicating metabolic activation (Fig. 4 C). Similar comparison of
cluster 9 versus all other clusters revealed that cluster 9 was
enriched in cell cycle genes, indicating a high proliferation rate
(Fig. 4 D). Clusters 7 and 9 shared 55 up-regulated DEGs (Fig. 4
E), many related to cell activation, whereas homeostatic mi-
croglia genes, such as P2ry12, were down-regulated in both
clusters. Gene ontology (GO) term enrichment of biological
processes supported these observations (Fig. 4, F and G). Mi-
croglia from AL002c-treated mice showed overall up-regulation
of markers of activation and proliferation (Top2a, Ifi27l2a, and
Spp1) across all clusters compared with microglia of control-
treated mice (Fig. 4 H). We conclude that acute engagement of
hTREM2 on microglia by AL002c promotes a signature of met-
abolic activation and proliferation distinct from that of DAM.
Sustained AL002c treatment has a negligible impact on Aβ
load in 5XFAD mice expressing hTREM2
Wenext investigated the potential therapeutic impact of AL002c
on Aβ load in the 5XFADmodel of Aβ aggregation. In this model,
plaques become clearly detectable at 3–4 mo of age and continue
to grow for several months (Oakley et al., 2006). We crossed
5XFAD mice with CV-KO and R47H-KO to generate CV-KO-
5XFAD and R47H-KO-5XFAD mice, respectively. These mice
were treated with weekly i.p. injections of AL002c or a control
IgG (30 mg/kg). To mimic a therapeutic treatment, we initiated
injections at 5 mo of age, when mice have already developed Aβ
aggregation, and continued until 8 mo of age, when Aβ plaques
are still growing (Fig. 5 A). The presence of effective AL002c
concentrations was verified in the cerebellum at the end of the
experiment (Fig. 5 B).
To determine the impact of AL002c on total Aβ plaque load,
we stained matched coronal brain sections with methoxy-X04
and measured total fibrillar plaque area in the cortices and
hippocampi by confocal fluorescence microscopy. We found no
differences in the total brain area covered by methoxy-X04
between AL002c- and control IgG-treated CV-KO-5XFAD and
R47H-KO-5XFAD mice (Fig. S4 A). Additionally, the overall
distribution of plaques size was similar whether mice were
treated with AL002c or control IgG (Fig. S4 B).
We next determined levels of Aβ1–40 and Aβ1–42 in the soluble
and insoluble fractions of hippocampus. Flash-frozen tissue was
homogenized sequentially in PBS and guanidine solutions to
obtain PBS-soluble and -insoluble fractions. Aβ1–40 and Aβ1–42
levels were measured in both fractions by the Meso Scale Dis-
covery (MSD) approach. Hippocampal regions of AL002c-
treated mice had slightly lower levels of soluble Aβ1–40 and
Aβ1–42 compared with control IgG-treated mice, whereas levels
of insoluble Aβ1–40 and Aβ1–42 were similar (Fig. S4, C–F). Cor-
tices of AL002c- and control-treated mice had similar levels of
insoluble Aβ1–40 and Aβ1–42 and no detectable soluble Aβ1–40 and
Aβ1–42 by MSD (not depicted). We conclude that the impact of
AL002c on soluble and insoluble Aβ load is small or negligible.
Wang et al. Journal of Experimental Medicine 4 of 19
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Figure 2. scRNA-seq analysis of microglia in treated mice. (A) Schematic of the scRNA-seq experiment. (B) UMAP of microglia subclustered from all Cd45+
cells. HM1-5, homeostatic microglia; TM, transitioning microglia; IRM, interferon-response microglia; PM1-2, proliferating microglia; SM, S-phase microglia.
(C) Gene expression heatmap for clusters defined as microglia. Genes shown are the top gene markers for each cluster defined byWilcoxon rank-sum test. The
number of cells per cluster is denoted above the cluster label. (D)Mean normalized expression of key signature genes across clusters. Error bars represent SEM
from all cells within the cluster. (E) Normalized expression of key signature genes on UMAP.
Wang et al. Journal of Experimental Medicine 5 of 19
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AL002c treatment reduces filamentous plaques and
neurite dystrophy
Because TREM2 sustains the formation of a microglia barrier
that promotes amyloid compaction and insulation and prevents
neurite dystrophy (Yuan et al., 2016; Wang et al., 2016), we
examined the impact of AL002c on amyloid compaction and
neurite dystrophy. Plaques were detected by staining brain
sections withmAb 6E10, which identifies Aβ aggregates whether
they have β-sheet or non–β-sheet conformations. Aβ aggregates
with a β-sheet conformation were further identified by staining
with methoxy-X04. Using this immunofluorescence approach,
we distinguished three types of plaques (Fig. 5 C). Filamentous
Figure 3. Impact of antibody treatment and TREM2 variants on microglia clusters. (A) Comparison of genes’ mean cluster z-scores from microglial
clusters (x axis) to gene signatures (y axis) taken from Sala Frigerio et al. (2019) and Keren-Shaul et al. (2017). (B) Fraction of all cells belonging to the microglia
clusters or other Cd45+ cells. (C) Fraction of cells in each cluster for each antibody treatment (adjusted for number of cells belonging to each mouse).
(D) Identical to C except for combined genotype and antibody categories. (E) Identical to C except for mice.
Wang et al. Journal of Experimental Medicine 6 of 19
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Figure 4. AL002c expands metabolically active and proliferating microglia. (A and B) Bar plot of the percentage of cells in cluster 7 (**, P = 6.4 × 10−3; A)
and cluster 9 (**, P = 3.4 × 10−3; B) on a per-mouse basis. Data are presented as mean ± SEM. (C) Wilcoxon rank-sum tests comparing cluster 7 to cluster
1 (homeostatic microglia). Genes above the −log(FDR adjusted P values) cutoff of 100 are annotated. (D) Identical to C except comparing cluster 9 to all other
clusters. FC, fold-change. (E) Venn diagram showing the number of shared DEGs found with Wilcoxon rank-sum test for cluster 7 and cluster 9. Cluster 7’s
DEGs were computed by comparing cluster 7 to cluster 1. Cluster 9’s DEGs were computed by comparing cluster 9 to all other clusters. (F and G) GO term
analysis for positive fold-change DEGs in cluster 7 and cluster 9. (H)Mean normalized gene expression grouped by TREM2 variant and antibody treatment in all
microglia.
Wang et al. Journal of Experimental Medicine 7 of 19
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plaques consist of Aβ aggregates with little β-sheet conformation
(6E10+, methoxy-X04lo/−) and branched amyloid fibrils that
protrude into the brain parenchyma, causing severe axonal
swelling. Inert plaques comprise Aβ aggregates that form a
compact β-sheet core with no Aβ radiating into the surrounding
parenchyma (6E10−, compact methoxy-X04+ core). Compact
plaques also have a compact β-sheet core but exhibit non–β-
sheet protrusions (6E10+, compact methoxy-X04+ core), which
are indicative of moderate neurotoxicity. In comparison to
control treatment, administration of AL002c induced an overall
significant reduction of filamentous plaques across the CV and
R47H genotypes, which was paralleled by an increase of inert
plaques, whereas the number of compact plaques was similar in
the two groups (Fig. 5, D–F). In pairwise comparisons, the effect
of AL002c on filamentous and inert plaques was more signifi-
cant in the CV than the R47H genotype, suggesting that the
ability of TREM2 to bind ligands, which is impaired in the R47H
variant, may impact the effectiveness of AL002c treatment.
Given the differential neurotoxicity of filamentous, inert and
compact plaques, we next examined whether changes in plaque
Figure 5. AL002c reduces soluble Aβ load and modifies the conformation of Aβ plaques. (A) Timeline of AL002c treatment in CV-KO-5XFAD or R47H-
KO-5XFAD mice. 5-mo-old mice were injected i.p. with AL002c at 30 mg/kg weekly for 12 wk. Littermates were administered the same concentration of IgG as
a control group. The behavioral test was performed after the 10th injection. Brains were harvested within 48 h after the last antibody injection. (B) AL002c
concentrations in the cerebellum at the end of chronic treatment. To capture AL002c, brain lysates from AL002c- or IgG-treated mice were incubated with
sTREM2 immobilized on plastic, followed by a secondary antibody. Only brain lysates containing AL002c but not control IgG test positive in this assay.
(C) Representative confocal images from the cortex of CV-KO-5XFAD mice treated with AL002c stained with 6E10 (red) and methoxy-X04 (green), displaying
three different forms of Aβ plaques. Red, green, and yellow arrowheads indicate filamentous, inert, and compact plaques, respectively. Bar = 100 µm.
(D–F) Percentages of filamentous, inert, and compact plaques in each treatment group of mice. A total of 1,604 plaques were analyzed. CV-KO-5XFAD, AL002c,
n = 6; CV-KO-5XFAD, IgG, n = 7; R47H-KO-5XFAD, AL002c, n = 6; R47H-KO-5XFAD, IgG, n = 6. Each symbol represents data of onemouse. *, P < 0.05; **, P < 0.01 by
two-way ANOVA. Although the overall effect of AL002c was significant across the CV and R47H genotypes in D and E, the AL002c effect was greater in the CV than
the R47H genotype. Accordingly, in pairwise comparisons, AL002c treatment was significant in the CV but not the R47H genotype (P = 0.0066 and 0.1002 for D; P =
0.00257 and 0.3275 for E; from pairwise comparison of the fitted least square mean from the linear model). No significant interaction between antibody treatment
and genotype was found. Data are presented as mean ± SEM and depict one experiment representative of three independent experiments.
Wang et al. Journal of Experimental Medicine 8 of 19
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profiles induced by AL002c impacted neuronal damage. We
stained brain sections for the N terminus of amyloid precursor
protein (APP), which accumulates in dystrophic neurites, and
measured N-terminal APP+ neuronal processes within 0–30-µm
spherical shells surrounding Aβ plaques (Fig. 6 A). We found
that the number, volume, and coverage of dystrophic neurites
per plaque were significantly decreased in mice treated with
AL002c versus control IgG across the CV and R47H genotypes
(Fig. 6, B–D). In pairwise comparisons, the effect of AL002c on
volume and coverage of dystrophic neurites was also significant
for each genotype. Thus, AL002c reduces the formation of
“neuritic” plaques and the associated induction of swollen, de-
generating axons and dendrites.
Mice treated with AL002c exhibit changes in exploratory drive
and anxiety-like traits
We next examined whether the reduction of Aβ pathology in-
duced by AL002c treatment was associated with behavioral
changes. It has been established that 5XFAD mice have an ab-
normal behavior in the Elevated Plus Maze (EPM) test compared
with WT mice (Braun and Feinstein, 2019; Hüttenrauch et al.,
2017). EPM is designed to assess risk-taking behavior, explora-
tory drive, and anxiety-like traits by giving mice free access to a
maze that contains both open unprotected arms and enclosed
protected arms, all elevated ∼1 m from the floor. In previous
studies, 5XFADmice were shown to explore the open anxiogenic
areas more than WT mice, demonstrating that Aβ pathology is
associated with increased risk-taking behavior and exploratory
drive, whereas anxiety-like behavior is subdued (Braun and
Feinstein, 2019; Hüttenrauch et al., 2017). Therefore, we chose
the EPM to explore the behavioral impact of AL002c.
When CV-KO-5XFAD and R47H-KO-5XFAD mice were tested
in EPM, the number of entries and the distance traveled in open
arms were significantly reduced in AL002c-treated mice com-
pared with control IgG-treated mice (Fig. 6, E–G). In contrast,
the time of immobility was increased (Fig. 6 H), indicating de-
creased exploration of the maze. In control tests of locomotor
activity, antibody treatment did not affect general exploratory
behavior or locomotion, suggesting that the observed differ-
ences were specific to the EPM (Fig. 6, I and J). We conclude that
AL002c treatment restores fear of heights and open spaces and
mitigates risk-taking behavior and exploratory drive in CV-KO-
5XFAD and R47H-KO-5XFAD mice.
Treatment with AL002c impacts microglia response to Aβ
We next directly examined the impact of AL002c on microglia.
We first performed immunofluorescence analysis of cortices and
hippocampi by staining for the microglial marker Iba1. Quanti-
fication of total Iba1+ area throughout the brains of CV-KO-
5XFAD mice and R47H-KO-5XFAD mice revealed no significant
difference whether mice were treated with AL002c or control
IgG (Fig. S5, A–C). We next measured the microglia clusters
within 0–15-µm and 0–30-µm spherical shells surrounding Aβ
plaques by positioning Iba1+ microglia and methoxy-X04+ pla-
ques in a semiautomated workflow in Imaris and Matlab. As we
reported previously (Song et al., 2018), CV-KO-5XFAD showed
more microglia coverage of Aβ plaques than R47H-KO-5XFAD
mice (Fig. S5, D–F). Coverage was not increased by AL002c in
the hippocampi of both strains, and was in fact slightly reduced
in the cortex of CV-KO-5XFAD mice (Fig. S5, D–F).
To further examine the impact of AL002c on microglia, we
measured the cell body size and the total length of processes by
which microglia monitor their surroundings (Davalos et al.,
2005; Nimmerjahn et al., 2005). Interestingly, both parameters
were increased in the cortices and hippocampi of AL002c-
treated mice compared with control IgG-treated mice, suggest-
ing increased surveillance activity (Fig. 7, A–C). Moreover, we
stained microglia for CD68, a marker of activation and phago-
cytosis, as well as Aβ42. Three-dimensional reconstruction of
Aβ42 and CD68 immunofluorescence demonstrated that AL002c
treatment increased the ratio of Aβ42+CD68+ microglial phag-
osomes over total Aβ42, suggesting that anti-TREM2 promotes
microglial activation and phagocytosis of Aβ (Fig. 7, D and E).
Together, these data suggest that AL002c increases microglial
surveillance and phagocytic activities, although no obvious in-
crease in microglia clustering around plaques is detectable.
Statistical analysis revealed an interaction between AL002c
treatment and mouse genotypes, such that AL002c had a greater
impact on the morphology and phagocytic capacity of CV-KO-
5XFAD microglia than on R47H-KO-5XFAD microglia. As dis-
cussed above, the disparate impact of AL002c treatment may
depend on the different ability of TREM2 variants to bind
ligands.
Finally, we stained brain sections for Iba1 and the inflam-
mation marker Spp1. As we reported previously (Song et al.,
2018), CV-KO-5XFAD showed more microglial expression of
Spp1 than R47H-KO-5XFAD mice. Treatment with AL002c was
associated with reduced expression of Spp1 within Iba1+ cells
compared with control IgG treatment in both strains (Fig. 7, F
and G). To corroborate this result, we measured soluble Spp1 in
the brain lysates of hTREM2-Bac-Tg crossed with 5XFAD mice
that had been chronically treated with AL002c or control IgG.
AL002c reduced soluble Spp1 compared with control IgG (Fig.
S5 G). These results suggest that AL002c-induced increase of
microglial phagocytosis may be associated with reduced in-
flammatory activity.
AL002 is well tolerated in a first-in-human phase I clinical trial
Finally, we report the results from a first-in-human phase I trial
of AL002, the clinical variant of AL002c. The main objectives of
this phase I study (NCT03635047) were to assess the safety,
tolerability, pharmacokinetics and pharmacodynamic effects of
AL002. In the single ascending dose (SAD) stage of the phase I
study, 56 healthy adult participants were sequentially enrolled
in 10 cohorts (A–I and K) and received a single i.v. dose of AL002
ranging from 0.003 to 60 mg/kg. SAD cohorts A–C contained
one participant on active drug per cohort, cohorts D–H consisted
of eight participants per cohort (six active, two placebo), and
cohort I included seven participants (six active, one placebo); in
one open-label cohort (K), six participants were treated with
active drug at 45 mg/kg. For cohorts F–K, lumbar punctures
were performed before and 2 d after doses to obtain cerebro-
spinal fluid samples to measure sTREM2 and soluble CSF-1R
(sCSF-1R) levels. All subjects were followed out to 12 wk after
Wang et al. Journal of Experimental Medicine 9 of 19
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Figure 6. AL002c ameliorates neuronal damage and impacts anxiety-like traits. (A) Representative confocal images from the cortex of indicated groups
of mice, showing methoxy-X04-labeled Aβ plaques (blue) and surrounding N terminus-APP+ neurites (red). Bars = 100 µm; insets, 25 µm. (B–D)Quantification
of number (B), coverage (C), and volume (D) of dystrophic neurites per plaque in the indicated groups of mice. Each CV-KO-5XFAD treatment group, n = 7; each
R47H-KO-5XFAD treatment group, n = 6. The effect of AL002c was significant across CV and R47H genotypes: **, P < 0.01 by two-way ANOVA. In C and D, the
effect of AL002c was also independently significant in the CV and R47H genotypes in pairwise comparisons (P = 0.0293 and 0.019 for C; P = 0.0371 and 0.0409
for D; from pairwise comparison of the fitted least square mean from the linear model). (E–H) Anxiety-like traits in mice behavior were evaluated by EPM and
are presented as total entries into open arms (E), distance in open arms (F), total distance (G), and total immobile time (H). (I and J) AL002c treatment does not
affect general locomotor activities. Total ambulations and time at rest were quantified over a 60-min period in transparent enclosures. CV-KO-5XFAD, AL002c,
n = 6; CV-KO-5XFAD, IgG, n = 6; R47H-KO-5XFAD, AL002c, n = 13; R47H-KO-5XFAD, IgG, n = 7. Each symbol represents data of one mouse. *, P < 0.05; **, P <
0.01 by two-way ANOVA. No significant interaction between antibody treatment and genotype was found. Data are presented as mean ± SEM.
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Figure 7. Impact of AL002c onmicroglial responses to Aβ. (A)Morphology of microglia associated with plaques (blue) highlighting the shape of cell bodies
(red) and primary processes (cyan) in the cortex (Ctx) of indicated groups of mice. Bar = 20 µm. (B and C) Cell body volume (B) and average length of primary
processes (C) of plaque-associated microglia were measured by Imaris using z-stack confocal images. Images of total 21 or 18 plaques with >180 microglia per
treatment group were analyzed. Each CV-KO-5XFAD treatment group, n = 7; each R47H-KO-5XFAD treatment group, n = 6. **, P < 0.01; ***, P < 0.001 by two-
way ANOVA. HC, hippocampus. (D) Representative confocal images by three-dimensional reconstruction of the cortex of indicated groups of mice, depicting
engulfed Aβ (red) by CD68+ phagosome (green). Bar = 25 µm. (E) Quantification of the ratio of Aβ colocalized with CD68 over total Aβ volume. n = 4 for each
treatment group. Each symbol represents data of one mouse. *, P < 0.05 by two-way ANOVA. A significant interaction was detected between antibody
treatment and genotype in C and E, such that the effect of the antibody treatment is greater in the CV-KO-5XFAD than the R47H-KO-5XFAD genotype. Data are
presented as mean ± SEM. (F) Representative confocal images of the cortex of the indicated groups of mice, depicting Aβ plaques (methoxy-X04, blue), Iba1
(red), and Spp1 (green). Bar = 100 µm. (G) Quantification of the percentage of Spp1+ pixels within Iba1+ pixels in the indicated genotypes of mice (CV-KO-
5XFAD, AL002c, n = 7; CV-KO-5XFAD, IgG, n = 7; R47H-KO-5XFAD, AL002c, n = 6; R47H-KO-5XFAD, IgG, n = 6). Each symbol represents data of one mouse. **,
P < 0.01 by two-way ANOVA. No interaction between antibody treatment and genotype was detected. Data are presented as mean ± SEM.
Wang et al. Journal of Experimental Medicine 11 of 19








niversity In St. Louis Libraries user on 11 Septem
ber 2020
dosing. AL002 was generally safe and well tolerated, with no
drug-related serious adverse events or dose-limiting toxicities
up to the highest dose (Table 1).
sTREM2 and sCSF-1R are biomarkers of AL002 treatment
As part of the phase I study, we assessed the effect of AL002 on
cerebrospinal fluid biomarkers. Administration of a single dose
of AL002 caused a dose-dependent decrease in sTREM2 from
baseline within 2 d that was paralleled by an increase in sCSF-1R
(Fig. 8). sTREM2 is the product of proteolytic cleavage of cell-
surface TREM2 (Piccio et al., 2008; Wunderlich et al., 2013;
Schlepckow et al., 2017; Feuerbach et al., 2017). A decrease in
cerebrospinal fluid sTREM2 may indicate that AL002 interferes
with proteolytic shedding, by blocking the cleavage site; how-
ever, it may also induce the internalization of TREM2, thereby
reducing surface TREM2 available for cleavage. Whether a re-
duction of sTREM2 in the brain contributes to the beneficial
effect of the antibody remains to be determined. sCSF-1R is the
cleavage product of transmembrane CSF-1R, which is only ex-
pressed by microglia in the brain. The increase of sCSF-1R may
indirectly reflect the increased proliferation of microglia docu-
mented in our mouse model by scRNA-seq. Whether sCSF-1R
acts a decoy receptor that regulates microglia expansion dur-
ing AL002 treatment or has another function remains to be
established.
Discussion
In this study, we found that a single injection of the hTREM2
agonistic mAb AL002c in the 5XFADmodel of AD expressing the
hTREM2 transgene acutely expanded microglial subsets that are
metabolically active and proliferate. Moreover, prolonged sys-
temic administration of AL002c reduced filamentous Aβ plaques
and neurite damage. Subtle but significant changes in risk-
taking and anxiety-like traits paralleled the reduced pathology.
Immunofluorescence analyses of microglia showed signs of in-
creased surveillance activity and Aβ phagocytosis, as well as
reduced expression of the inflammatory marker Spp1. We con-
clude that mAb-mediated engagement of hTREM2 enhances
neuroprotective microglia, restraining neurotoxic Aβ plaques
and neuronal damage.
It has been thought that TREM2-dependent clustering of
microglia around plaques is essential for containing Aβ plaques
and associated neuropathology. In our study, mice treated with
AL002c evinced neither a reduction of total Aβ load nor an in-
crease in microglia clustering around Aβ plaques. AL002c-
mediated activation of microglia may be insufficient to cope
with the rapid accumulation of Aβ characteristic of the 5XFAD
model. Nevertheless, AL002c was sufficient to reduce Aβ plaque
toxicity and attenuate neuritic dystrophy, which is one of the
important pathological features associated with AD and age-
dependent neuronal dysfunction (Lombardo et al., 2003;
Serrano-Pozo et al., 2010; Mucke and Selkoe, 2012). Microglia
repeatedly activated by AL002c may act in part by removing
oligomeric Aβ and Aβ seeds rather than plaques, as well as by
clearing dystrophic neurons and producing neuroprotective
factors. Attenuation of Aβ-induced pathology may also explain
the observed diminution of microglial clustering and inflam-
mation, which may be beneficial in this context. Consistent with
our results, overexpression of hTREM2 in a mouse model of AD
had beneficial effects on the disease in conjunction with di-
minished microglial clustering (Lee et al., 2018).
A very recent paper showed that injection of an agonistic
anti-mouse TREM2mAb at 3-d intervals for 10 d reduced the Aβ
plaque load in the APP-NL-G-F knock-inmodel of AD (Schlepckow
et al., 2020). Whereas we observed a clear effect of the anti-
hTREM2 mAb AL002c on microglial proliferation, neurite dys-
trophy, and behavior, we did not detect any significant change in
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plaque load. Numerous factors could contribute to this discrep-
ancy: different mAbs were administered according to disparate
administration regimens, distinct mouse models of Aβ accumu-
lation were used, and mice were analyzed at different ages.
Clearly, more studies are warranted to compare various thera-
peutic regimens that entail different doses and/or frequencies of
mAb administration, as well as disparate mouse models of AD
pathology.
Our scRNA-seq analysis of microglia in AL002c-treated mice
broadens our knowledge of microglia heterogeneity in the
5XFAD model by delineating a spectrum of microglial subsets
that includes not only previously identified homeostatic, DAM,
and IFN-responsive microglia, but also two novel subsets with
distinct metabolic and proliferation profiles. These two clusters
expanded after a single injection of anti-TREM2, whereas a
homeostatic cluster tended to contract in parallel, suggesting
that metabolically active and proliferating microglia derive from
homeostatic microglia. scRNA-seq analysis at later time points of
treatment will be necessary to see whether subsets that expand
early after AL002c administration persist as such, convert into
DAM in response to Aβ-induced tissue damage, or return into a
homeostatic state when mAb activation terminates or Aβ pa-
thology is attenuated.
In this study, we evaluated AL002c on both the CV and R47H
variants of hTREM2 in vivo. Acute TREM2 stimulation had a
more impressive impact on microglia proliferation in R47H than
in CV mice; conversely, prolonged TREM2 stimulation had a
more beneficial impact on Aβ-induced pathology in CV mice
than in their R47H counterparts. Because CV is continuously
bound to lipids, Aβ, and other ligands in vivo, whereas R47H is
not, we speculate that R47H may be more responsive to mAb-
mediated cross-linking than CV. In the long term, however,
heightened responsiveness of R47H may lead to excessive acti-
vation and exhaustion. It is also possible that the long-term
beneficial effects of mAb-activated microglia on brain pathol-
ogy depend on the ability of TREM2 to effectively bind lipids,
apoptotic cells, and Aβ.
Can anti-hTREM2mAbs provide a valid therapeutic approach
for AD? Our results show that AL002c treatment of 5XFAD mice
was beneficial when Aβ aggregation was already ongoing and Aβ
plaques formed, suggesting that anti-TREM2 antibodies may be
helpful even if introduced at relatively late stages of disease.
Future studies should further define the broad impact of AL002c
treatment on memory and learning behaviors other than the
subtle but significant impact on risk-taking and fear-conditioning
reported here. Importantly, we reported preliminary data from
the first-in-human phase I clinical trial with AL002, which in-
dicates that AL002 administration was generally safe and well
tolerated,and that its activity can be traced in the cerebrospinal
fluid through two biomarkers, sTREM2 and sCSF-1R, which cor-
roborate specific target engagement. Thus, results presented here
overall support that anti-TREM2 antibodies, such as AL002,
are promising candidates for AD therapy. This approachmay have
broader neuroprotective effects than plaque removal andmay be a




TREM2tm1(KOMP)Vlcg mice were immunized by ImmunoPre-
cise with hTREM2-Fc recombinant protein using standard pro-
cedures. Bleed titers were evaluated in in vitro assays, such as
ELISA or FACS. Animals with a good immune response to the
antigen were selected for fusion and given a final i.v. boost of
antigen without adjuvant. Lymphocytes were isolated from the
immunized animals and fused with mouse myeloma cells using
polyethylene glycol (PEG 1500; Roche, 10783641001) according
to the manufacturer’s instructions. Fused cells were plated into
semisolid methylcellulose-based medium containing hypoxan-
thine, aminopterin, and thymidine for 10–12 d, allowing for
single-step cloning and hybridoma selection. Single colonies
were picked and transferred to 96-well plates containing culture
medium with hypoxanthine-thymidine and grown for 4–5 d
until mid-log-phase growth was reached. Supernatants were
screened by ELISA for IgG production, isotype, and antigen
specificity and by FACS for binding to native antigen on cells.
Positive hybridoma clones were subcloned using a single-step
cloning system to ensure monoclonality, and the subclone su-
pernatants were rescreened by FACS to confirm specificity. Fi-
nal subclones were expanded in culture, and the supernatants
were purified by Protein-A affinity chromatography. Purified
antibodies were tested in vitro for specificity, functional activ-
ity, binding affinity, and epitope binning. The parental clone of
AL002c was selected for its ability to activate hTREM2.
Adimab yeast platform was used for humanization and
affinity maturation. Briefly, for humanization of the lead anti-
body 9F5, Adimab generated 94 humanized versions of 9F5 by
Figure 8. Biomarkers in first-in-human phase I
clinical trial. (A and B) Administration of a single
dose of AL002 caused a dose-dependent decrease
in cerebrospinal fluid of sTREM2 (A) from baseline
within 2 d that was paralleled by an increase in
sCSF-1R concentration (B). P = 0.0001 for 6 mg/kg
and P < 0.0001 for all other doses vs. pooled pla-
cebo control (A) and P = 0.026 at 60 mg/kg vs.
pooled placebo (B) by mixed-model repeated mea-
sures analysis adjusted for multiplicities using Dun-
nett’s test. Data are presented as mean ± SD; cohort
n = 6 (placebo, 6 mg/kg, 15 mg/kg, 30 mg/kg) and 5
(45 mg/kg, 60 mg/kg).
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combining 21 huIgG1 versions of VH with 6 huIgG1 versions of
VK, each containing 0–11 framework residue mutations. Anti-
bodies were tested for binding to hTREM2 and agonistic activity,
and the top two humanized versions were affinity matured. For
affinity maturation, key amino acid residues in the heavy or
light chain genes of the humanized parental clones were selec-
tively mutagenized, and mutants that improved binding were
selected through additional rounds of screening. Antibodies
with improved affinity, based on Forte Bio and MSD measure-
ments, were further screened for improvement in cell-based
binding affinity and agonistic activity in a luciferase reporter
assay. Finally, liability amino acids were replaced.
Mice
CV-KO-5XFAD and R47H-KO-5XFAD mice were generated as
previously described (Song et al., 2018). Mice were housed in
the animal facilities of Washington University in St. Louis. All
animal experiments were conducted in compliance with in-
stitutional regulations, under authorized protocol #20160220
approved by the Institutional Animal Care and Use Com-
mittee. hTREM2-Bac-Tg mice were generated by using the
bacterial artificial chromosome (BAC) clone CTD-3222A20
(Invitrogen/Life Technologies/Thermo Fisher Scientific). This
BAC covered a contiguous region from nucleotide 41104901 to
41292419 (based on hg38 build of UCSC) spanning 187,519
nucleotides and harboring the complete sequences of the
hTREM2, TREML2, TREM1, TREML1, and TREML4 genes. The
purified BAC DNA was injected into mouse C57BL6/j zygotes
by standard pronuclear injection techniques. Zygotes were
returned to females, and the resulting pups were genotyped
for the presence of the transgene. Founder animals harboring
the transgene were then bred to nontransgenic animals, and
progeny were screened for expression of the transgene using
standard techniques.
Tissue preparation
BM was collected from femurs and tibias as described before
(Ulland et al., 2017). To prepare BMM for antibody binding,
survival, and immunoprecipitation assays, BM cells were counted
and plated at 10 × 106 cells/100-mm Petri dish in RPMI supple-
mented with Glutamax, penicillin/streptomycin, nonessential
amino acids, pyruvate, 10% heat-inactivated fetal bovine serum
(complete RPMI) and 50 ng/ml CSF-1 (Peprotech). Cells were
cultured for 7 d before use.
To perform scRNA-seq of the immune cells in brain, whole
brains of 22-wk-old (5.5 mo) mice from AL002c- or control IgG-
treated groups were dissected after transcardial perfusion with
ice-cold PBS and dissociated as previously described (Song et al.,
2018). Immune cells were recovered after Percoll (GE) separa-
tion, as described (Mildner et al., 2007).
To perform the biochemical analysis of brain after AL002c
chronic treatment, brains were removed after transcardial perfu-
sion with ice-cold PBS. Cortex and hippocampus were dissected out
from left brain hemispheres and flash frozen; right brain
hemispheres were fixed in 4% PFA for 2 d at 4°C and rinsed in
PBS before incubation for 2 d at 4°C in 30% sucrose. Dehydrated
brain tissues were frozen in a 2:1 mixture of 30% sucrose and
optimal cutting temperature compound for obtaining serial
40-µm cryosections.
Antibody binding assay
BMM from CV-KO and R47H-KO were harvested at day 7 and
stained in FACS buffer (2% FCS in PBS) with anti-hTREM2
AL002c-dylight 650 and isotype CTR-dylight 650. Human Fc-
block (14-9161-73, eBioscience) was added to the mix. Dead
cells were stained with live/dead staining kit (Invitrogen).
Survival assay
Humanmacrophages or BMMwere harvested at day 7 of culture
and plated in 96-well flat-bottom plates at 5 × 105/well in com-
plete RPMI without CSF-1. Survival, measured as ATP content,
was detected after 5-d culture with CellTiter-Glo luminescent
viability assay (Promega).
EGFP reporter assay
2B4 NFAT:EGFP reporter cells expressing hTREM2-CV and 2B4-
hTREM2-R47H have been described (Song et al., 2017). Phos-
phatidylcholine (Avanti, 840051P) was reconstituted in methanol
at 100 ng/µl, and 50 µl was added to each well as a positive
control. Plates were allowed to dry by evaporation at room
temperature, leaving phosphatidylcholine coated on the well
bottom. Next, stock solutions of AL002c or control IgG were di-
luted to the indicated concentrations in medium, and 50 µl of the
resulting solution was added to distinct wells within the same
plate coated with phosphatidylcholine. Each condition was per-
formed in triplicate. After preparation of the plate, 50,000 cells in
50 µl of complete RPMIwith 5% fetal bovine serumwere added to
the corresponding wells. After 24 h, the cells were transferred to
FACS tubes and read on a FACSCalibur for EGFP expression.
Luciferase reporter assay
BW5.147G14 cells (ATCC) were infected with a retrovirus encoding
hTREM2 and DAP12, as well as an NFAT:luciferase carrying virus
(Qiagen). Cells were stimulatedwith two concentrations of AL002c
or control IgG in solution for 6 h, and luciferase expression was
measured by adding OneGlo reagent (Promega) according to
manufacturer’s instructions. Luminescence was measured on the
Biotek Synergy H1 plate reader.
Immunoprecipitation in vitro
Before stimulation, BMM were starved for 4 h in 1% serum
RPMI. 10 × 106 cells were incubated on ice for 15 min with 1 µg
of antibody per million of cells. Cells were then washed and
incubated at 37°C for the indicated period of time in the
presence of goat anti-mouse IgG (1.5 µg for 106 cells). After
stimulation, cells were lysed with lysis buffer (1% n-dodecyl-
β-D-maltoside, 50 mM Tris-HCl, pH 8.0, 150 mM NaCl, 1 mM
EDTA, 1.5 mM MgCl2, and 10% glycerol, plus protease and
phosphatase inhibitors) and immunoprecipitated with anti-
TREM2 (clone 237920, R&D Systems) or isotype control. Precipi-
tated proteins were fractionated by SDS-PAGE in nonreducing
conditions, transferred to PVDF membranes, and probed with
anti-phosphotyrosine antibody (4G10, Millipore). TREM2 is not
detected in nonreducing conditions. To confirm that each sample
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contained equal amounts of proteins, lysates were fractionated
by SDS-PAGE in reducing conditions. Immunoblots were then
stained with an anti-actin antibody (sc-47778, Santa Cruz) to
allow protein loading quantification.
Immunoprecipitation in vivo
6–8-wk-old C57BL/6 mice or hTrem2-Bac-Tg mice were injected
i.p. with 3 ml of 3% thioglycolate. After 3 d, when the peritoneal
cavity was enriched with peritoneal macrophages (CD11b+F4/80+)
expressing TREM2, mice were injected with control or AL002c
(40 mg/kg) for 24 h. Peritoneal cells were recovered and imme-
diately lysed in lysis buffer (n-dodecyl-β-D-maltoside 1%, 50 mM
Tris-HCl, pH 8.0, 150 mM NaCl, 1 mM EDTA, 1.5 mM MgCl2, and
10% glycerol, plus protease and phosphatase inhibitors) and im-
munoprecipitated with rat anti-human/mouse TREM2 (R&D Sys-
tems, clone 237920). Precipitated proteins were fractionated by
SDS-PAGE (nonreducing conditions), transferred to nitrocellulose
membranes, and probedwith anti-phosphotyrosine antibody (4G10,
Millipore). To confirm that all substrates were adequately im-
munoprecipitated, whole-cell lysates from each sample were
separately fractionated by SDS-PAGE in reducing conditions and
immunoblotted with goat anti-hTREM2 (R&D Systems).
scRNA-seq and computational analysis
Mice were reared for 5.5 mo. They were injected i.p. with
AL002c or IgG at 30 mg/kg 48 h before sacrifice. Whole brains
were perfused, dissociated, and sorted using FACS for Cd45+
cells. For AL002c treatment, we analyzed two CV-KO-5XFAD
and four R47H-KO-5XFAD mice. For IgG treatment, we analyzed
two CV-KO-5XFAD and three R47H-KO-5XFADmice. scRNA-seq
information has been deposited in the Gene Expression Omni-
bus database under accession number GSE150358.
scRNA-seq and read alignment
All Cd45+ cells were prepared via 10X Genomics v3 39 Gene Ex-
pression Kit and sequenced on NovaSeq flow cells to achieve a
read depth of 50,000 reads per cell and ∼2,000–8,000 cells per
sample. Demultiplexed FASTQs were aligned to the mouse ge-
nome (mm10 build) using 10X Genomics’ CellRanger v3.0.2 with
the command cellranger count with default parameters. Mouse-
level matrices were concatenated to produce the raw input UMI
count matrix. Cells were filtered out to remove low-viability and
poorly sequenced cells. We removed cells that had <200 genes
expressed and removed genes that were expressed in <3 cells,
that were outside the boundary defined by the median ± 4 ×
absolute SD of either the number of UMIs or the number of genes
detected, and that had >10% reads coming from mitochondrial
genes. 42,409 Cd45+ cells remained after this filtering, with a
median 7,363 UMIs per sample and average 3,855 cells per
mouse. To obtain hTREM2 expression levels, FASTQs were
aligned to the human genome (hg38 build). The resulting UMI
counts were normalized and scaled using the mouse UMImatrix.
Normalization, dimensional reduction, and clustering
The Seurat R package (Butler et al., 2018) was used for all
scRNA-seq analysis and processing. All steps were run using
default parameters unless otherwise noted. Log normalization
was performed on the UMI count matrix. The number of UMIs
per cell and percentage of mitochondrial reads per cell were
treated as undesired covariates and regressed out of the nor-
malized expression values. The normalized expression values
were scaled and centered for input into subsequent dimensional
reductions of principal component analysis (PCA) and UMAP.
PCA was performed using the top 2,000 variable genes identi-
fied using variance-stabilizing transformation. Cells were seg-
mented based on their neighbors (FindNeighbors Seurat function)
using the top 13 principal components (PCs) from PCA and
using only the top 2,000 variable genes. The number of
PCs used was based on the screen plot (i.e., a plot of the PC
eigenvalues in decreasing order). Other parameters of Find-
Neighbors were k.param of 12. To find cell clusters (FindClus-
ters Seurat function), a resolution of 0.4 was used. UMAP was
computed using the top 13 PCs, and cells were plotted onto the
first two UMAP dimensions.
Cell-type annotation
Cell types were manually classified based on well-known cell-
type gene markers. To classify cell types that were not T cells,
B cells, natural killer cells, or neutrophils, gene markers of dis-
tinct brain BAM subpopulations (Van Hove et al., 2019) were
used. To correctly classify all Cd45+ clusters, Seurat’s AddMo-
duleScore function was used to score each cell on each of the BAM
gene signatures (Van Hove et al., 2019). Cluster 18 was identified
as BAMs. Cluster 5 had a bimodal distribution of MHC class II
genes that separated the population of cells into MHC class II
high and low, but the granularity of clustering was not fine
enough to detect these subclusters (not depicted). Cluster 12 was
defined as monocytes, but we note that this cluster additionally
exhibited a high dural BAM score. Proliferating cells had high
expression of G2, M, and S phase genes (e.g., Top2a, Mki67, and
Mcm5).
Subsetting of microglia
Based on the clustering of all Cd45+ cells, clusters 0, 1, 2, 3, 4, 7, 8,
15, and 17 were kept for finer analysis. These clusters were se-
lected based on high microglial gene expression and low mito-
chondrial read percentage. Moreover, including these two
clusters in further analysis did not yield any different con-
clusions. These clusters contained 31,948 cells and comprised the
majority of Cd45+ cells (∼75%). Scaling and PCA were repeated
as stated above. Cells were clustered again (k parameter 12, top
2,000 variable genes, and resolution 0.45). UMAP dimensional
reduction was repeated with the top 25 PCs to help further vi-
sually separate clusters. Upon clustering this new subset of
microglia, a small cluster of cells was defined by myeloid and
lymphoid markers, indicating T cell and monocyte-like cells.
These cells were removed for subsequent analysis.
Microglia classification and gene signature scoring
For homeostatic microglia, cycling/proliferating microglia, and
IFN-responsemicroglia gene signatures, we reran the analysis of
the data from Chen et al. (2019) using only the AppNL-G-F versus
C57BL/6J mice data to recover the same microglial states the au-
thors did. We took the homeostatic microglia, cycling/proliferating
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microglia, and IFN-response microglia gene markers and scored
them in our microglial cells to create a score for each cell. Scoring
used the z-scores of that gene’s expression in all cells of a cluster.
DAM1 and DAM2 genes were taken from the supplemental figures
of Keren-Shaul et al. (2017). S-phase genes were taken from Tirosh
et al. (2016).
Differential expression
Differential expression was performed using functions in the
Seurat R package, namely FindAllMarkers and FindMarkers for
cluster-defining gene markers and specific cluster comparisons,
respectively. To calculate P values and average log fold-changes,
the Wilcoxon rank-sum test was used in conjunction with false
discovery rate (FDR) correction to adjust P values for multiple
hypothesis testing. To identify cluster-defining gene markers, we
compared one cluster to all other clusters. Genes that were ex-
pressed in 25% of the cells of a cluster and had absolute value >0.25
log fold-change were defined to be DEGs for that group. Cluster-
defining genes were defined using this differential expression.
GO enrichment analysis
After deriving lists of DEGs for each cluster, we sought to dis-
cover which biological process these genes implicate. Using only
positive expression fold-change DEGs that defined clusters, the
clusterProfiler function in Rwas used to run hypergeometric tests
to obtain probability significance levels. These P values were
adjusted using FDR. We pulled out enriched genes and biological
processes ontologies in which they were found. For plotting
purposes, P values were transformed by applying −log base 10 to
produce adjusted P values. Only the top 10 biological process hits
were plotted, and the ratios of genes belonging to the GO term
from the full list of DEGs were labeled.
Normalizing group-level proportions
Because of varying levels of the number of cells in each exper-
imental group, a correction was implemented to adjust for the
number of cells in each group when comparing group compo-
sitions within clusters. Group-level proportions within clusters
were adjusted to account for the raw number of observations of
each category in the group. For each group (e.g., cluster), we
divided the observation size of each category (e.g., mouse #3) by
fraction of cells in that category among all single cells. This gives
a value representing the n-corrected observation size. We di-
vided the n-corrected observation sizes by the n-corrected ob-
servation sizes summed across all categories. This is known as
the n-corrected category percentage, shown in Fig. 3.
Immunofluorescence
Brain sections were blocked with PBS + 3% BSA and per-
meabilized with 0.25% Triton X-100 in blocking solution. Pri-
mary antibodies were added overnight at a dilution of 1:5,000
for Iba1 (rabbit polyclonal, Wako), 1:1,000 for CD68 (rat mono-
clonal, BioLegend), and 1:500 for Aβ42 (rabbit recombinant
monoclonal, Thermo Fisher Scientific) or 1:1,000 for Aβ1–16
(6E10, BioLegend), 1:500 for Spp1 (goat polyclonal, R&D Sys-
tems), and 1:1,000 for APP (22C11 mouse mAb, Millipore) at 4°C.
Secondary antibodies were added as follows: anti-goat IgG Alexa
Fluor 488 (donkey polyclonal, 1:2,000; Abcam), anti-rabbit IgG
Alexa Fluor 555 (donkey polyclonal, 1:1,000; Abcam), anti-rat
IgG Alexa Fluor 555 (goat polyclonal, 1:1,000, Invitrogen), anti-
goat IgG Alexa Fluor 647 (donkey polyclonal, 1:1,000; Abcam),
anti-rabbit IgG Alexa Fluor 647 (goat recombinant polyclonal,
1:1,000; Invitrogen), anti-mouse IgG Alexa Fluor 647 (goat re-
combinant polyclonal, 1:2,000; Invitrogen) for 1.5 h at RT. Nuclei
were counterstained with TO-PRO-3 iodide (300 nM; Thermo
Fisher Scientific), and methoxy-X04 (3 µg/ml; Tocris) was used
to label Aβ plaques. The confocal pictures were taken on a Nikon
A1Rsi+ confocal laser-scanning microscope using a 20× 0.95-NA
objective. z-Stacks with 1.1-µm steps in the z direction, 1,024 ×
1,024-pixel resolution, were recorded. Three-dimensional re-
construction of microglia, plaques, and Aβ and dystrophic neu-
rons and extraction of parameters were performed in Imaris
v8.3 software (Bitplane), and further processing was analyzed
using automated scripts in Matlab (MathWorks).
Image analyses
For measurement of distinct Aβ plaque morphology, 6E10,
methoxy-X04, and merged z-stack images were exported from
Imaris. The conformation of individual plaque in each treatment
group of mice was determined as follows: filamentous, strong
6E10 staining without or less methoxy-X04 single; inert, only
methoxy-X04+ or concomitant with little 6E10 staining; and
compact, methoxy-X04+6E10+. The proportion of distinct plaque
morphology was calculated by normalizing the total number of
plaques from each z-stack image.
For measurement of methoxy-X04 area coverage, a similar
region encompassing portions of cortex or hippocampus was
drawn in ImageJ (National Institutes of Health) from individual
z-stack image. By setting up a threshold in which a fixed in-
tensity was much greater than the mean for the selected region,
the percentage of area coverage was calculated automatically by
batch processing in ImageJ. A similar procedure was performed
for quantification of Iba1 coverage in the cortex and hippo-
campus, with different threshold settings. The Surfaces function
of Imaris on methoxy-X04 images was used to calculate the
volume of individual plaques.
For measurement of neurite dystrophy around plaques, the
volumes of dystrophic neurites and plaque, as well as their
centers of mass, were determined using the Surfaces function of
Imaris on methoxy-X04 and APP image data. The number of
dystrophic neurites within 30 µm of plaque surfaces was de-
termined in Matlab as established before (Song et al., 2018). The
density of microglia around plaques was calculated by a similar
approach, in which the Spots function of Imaris was used to
identify microglia within the Iba1 and ToPro-3 colocalized
channel. The volume of microglial cell bodies was measured
using the Surfaces function. Lengths of the microglia processes
were determined by using the Filament function of Imaris as
described before (Wang et al., 2015).
For visualization of Aβ engulfed by microglial CD68+ phag-
osome, the Surfaces function on Aβ+, CD68+ and Aβ+CD68+ image
data was used to generate three dimensional reconstruction
images. The ratio of engulfed Aβ by phagosomewas calculated as
the total Aβ+CD68+ volume divided by the total Aβ+ volume.
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For measurement of Spp1+ pixels within Iba1+ pixels, the
Spots function on z-stack image data was used to conduct the
Iba1+ channel. The thresholds for Spp1+ within Iba1+ pixels were
determined by visual inspection and used for all images. For
each z-stack image, the percentages of Spp1+ pixels within Iba1+
pixels were calculated, and the ratio was calculated.
Aβ and Spp1 quantification
Cortical tissue and hippocampus were homogenized in PBS
containing protease inhibitor (Roche) at 0.5× concentration, and
remaining insoluble material was pelleted. Supernatant was
collected as the PBS-soluble fraction, and the pellet was re-
suspended in 5.5 M guanidine and 50 mM Tris, pH 8.0, buffer,
further homogenized, and incubated on a rotator for 3 h at room
temperature. The samples were centrifuged again to pellet in-
soluble material, and the supernatant was collected as the PBS-
insoluble guanidine fraction. Aβ1–40 and Aβ1–42 were measured
by MSD. Spp1 was measured by ELISA (R&D Systems).
Behavioral tests
The behavioral performance of CV-KO-5XFAD and R47H-KO-
5XFADwith control IgG or AL002c treatment was assessed in all
mice at 8 mo of age. Locomotor activity was used to measure
differences in general activity or emotionality between treat-
ment groups. Anxiety-related behavior was assessed in the EPM
similar to previously published methods (Wozniak et al., 2013;
Yuede et al., 2009). All behavioral testing was conducted during
the light cycle by a female experimenter blinded to experimental
group. All equipment was cleaned with 2% chlorhexidine diac-
etate or 70% ethanol between animals. The order of tests con-
ducted was locomotor activity and then EPM.
Open field activity/exploratory behavior
General activity levels and exploratory behavior were quantified
over a 60-min period in transparent enclosures (47.6 × 25.4 ×
20.6 cm) constructed of Plexiglas and surrounded by comput-
erized photobeam instrumentation (Kinder Scientific). General
activity variables (total ambulations, rearings, and time at rest)
along with measures of emotionality, including time spent,
distance traveled, and entries made into the central zone, were
analyzed.
EPM
EPM was conducted 1 d after locomotor activity assessment by
methods similar to those previously described (Wozniak et al.,
2013). Briefly, animals were placed on a dimly lit black acrylic
surface measuring 5 × 5 cm and elevated 63 cm above the floor,
equipped with photo beam pairs. Four arms (35 cm long, 5 cm
wide; two open and two with 15-cm-high walls) extended from a
central area. MotorMonitor software (Kinder Scientific) quan-
tifiedmovement as duration, distance traveled, entries, and time
at rest in each zone (closed arms, open arms, and center area).
Statistical analyses
All statistical analyses were performed using GraphPad Prism
software (v8). Before analyses, all data were screened for
missing values, fit between distributions and assumptions of
univariate analysis, and homogeneity of variance. ANOVA, in-
cluding repeated measures, was used to analyze the behavioral
data. With a statistically significant interaction between main
factors, simple main effects were calculated to provide clarifi-
cation of statistically significant differences with regard to
treatment. Where appropriate, the Greenhouse–Geisser correc-
tion was used to protect against violations of sphericity in
repeated-measures analyses, and Bonferroni correction was
applied to multiple pairwise comparisons and post hoc tests.
Probability value for all analyses was P < 0.05, unless otherwise
stated.
SAD part of the phase I study
56 healthy adult participants sequentially enrolled in 10 cohorts
(A–I, K) received a single i.v. dose of AL002 ranging from 0.003
to 60 mg/kg. SAD cohorts A–C contained one participant on
active drug per cohort; cohorts D–H consisted of eight partic-
ipants per cohort (six active, two placebo); and cohort I included
seven participants (six active, one placebo). In one open-label
cohort (K), six participants were treated with active drug at
45 mg/kg. For cohorts F–K, lumbar punctures were performed
before and 2 d after doses to obtain cerebrospinal fluid samples.
All subjects were followed to 12 wk after dosing.
sTREM2 assay in human cerebrospinal fluid
An immunoassay method was used for the determination of
sTREM2 in human cerebrospinal fluid based on an electro-
chemiluminescent methodology. A first anti-hTREM2 antibody
was diluted in coating buffer and immobilized onto a 96-well
microtiter sample plate. After blocking and washing of the plate,
endogenous quality control and study samples were diluted with
assay buffer, dispensed onto the sample plate, and incubated. A
second anti-hTREM2 antibody binding to a different bin from
the first was added as capture antibody. The plate was washed,
and Sulfo-Tag streptavidin was added and incubated, followed
by addition of MSD Read Buffer T. Concentrations were deter-
mined on a standard curve obtained by relative light units
versus concentration. The calibration curve was generated using
a 4-parameter curve fit with 1/y2 weighting. The qualified range
for this method in human cerebrospinal fluid is from 0.400 to
50.0 ng/ml.
sCSF-1R assay in human cerebrospinal fluid
A commercial ELISA assay by R&D Systems was used for the
determination of sCSF-1R in human cerebrospinal fluid. Human
M-CSF R capture antibody was diluted in coating buffer and
immobilized onto a 96-well microtiter sample plate. After
blocking and washing of the plate, endogenous quality control
and study samples were diluted, dispensed onto the sample
plate, and incubated. Human M-CSF R detection antibody was
added and incubated. The plate was washed, and Streptavidin-
HRP A was subsequently added followed by a working substrate
solution. The plate was incubated at ambient temperature,
stopped with the addition of Sulfuric Acid Stop Solution, and
read on a plate reader using two filters, 450 nm for detection and
570 nm for background. Concentrations were determined on
a standard curve obtained by plotting optical density versus
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concentration. The calibration curve was generated using a
4-parameter curve fit with 1/y2 weighting. The qualified range
for this method in human cerebrospinal fluid is from 125 to
4,000 pg/ml in 100% cerebrospinal fluid.
Statistical analysis
Two-way ANOVA was used to compare the independent effects
of both antibody treatment and TREM2 variant (genotype), in-
dividually, on quantifications. The aov function in R was used
with the format (data$y ~ data$antibody + data$genotype), and P
values were taken from the antibody variable unless otherwise
noted. scRNA-seq commonly uses n = 2 experimental design. We
performed scRNA-seq on more than n = 2 per condition to in-
crease the statistical power of our results even further, as n = 2 is
common for scRNA-seq experiments.
Online supplemental material
Fig. S1 shows that AL002c activates hTREM2 signaling and
function. Fig. S2 displays the pharmacokinetics of AL002c. Fig.
S3 shows scRNA-seq analysis of Cd45+ brain cells from antibody-
treated mice. Fig. S4 presents the impact of chronic AL002c
treatment on Aβ load. Fig. S5 shows the impact of chronic
AL002c treatment on microglia clustering around plaques and
Spp1 secretion.
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Supplemental material
Figure S1. AL002c activates hTREM2 signaling and function in vitro. (A) Parental, hTREM2-CV, and -R47H 2B4 reporter cell lines were stimulated with
plate-bound phosphatidylcholine. Live cells were gated and tested for EGFP expression. Stimulation of hTREM2-CV, and to a minor extent hTREM2-R47H,
induced EGFP. SSC, side scatter; FSC, forward scatter. (B) BW5.147G14 cells expressing hTREM2 (CV) were stimulated with two concentrations of AL002c or
control IgG in medium for 6 h, and luciferase expression was measured by adding OneGlo reagent. *, P < 0.05 by unpaired two-tailed t-test. Data are presented
as mean ± SEM. (C) Cell viability assay of hTREM2+macrophages treated with different concentrations of soluble AL002cwith intact Fc and mutated Fc (AL002
LALAPS). Data are presented as mean ± SD. (D) WT and hTREM2-Bac-Tg BMM were stimulated for 3 min with control IgG (CTR), anti-mouse TREM2 mAb
msAL002, or anti-hTREM2mAb AL002c, followed by cross-linkingwith a secondary antibody. Cells were then lysed and immunoprecipitated (IP) with a distinct
anti-TREM2 antibody and blotted with anti-phosphotyrosine antibody. For control loading, the membrane was stripped and probed with anti-DAP12 antibody.
(E) WT or hTREM2-Bac-Tg mice were injected at day 0 with 3% thioglycolate. At day 3, mice were injected with the AL002c or CTR antibodies. 24 h later,
peritoneal cells were collected, immunoprecipitated with anti-TREM2 antibody, and blotted with anti-phosphotyrosine antibody. For control loading, whole-
cell lysates were blotted with anti-hTREM2 antibody.
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Figure S2. AL002 pharmacokinetics. (A) Timeline of pharmacokinetics (PK) study of AL002 in TREM2-Bac-Tgmice. A single dose of AL002 was administered
on day 0 at 5, 20, and 60 mg/kg. Different mouse cohorts were sacrificed on days 1, 2, 4, 8, 14, and 21, and plasma and brain samples were collected for
measurement of antibody levels. (B) AL002 (human IgG) levels in plasma. (C) AL002 (human IgG) brain concentration in ng/ml was converted to ng/mg protein
assuming a brain volume of 0.5 ml and a protein content of 38 mg. Using this calculation, we observed that∼0.11% of AL002 penetrated in brain across all time
points and animals. The terminal half-life in TREM2-Bac-Tg mice ranged from 1 to 1.8 d. Data are presented as mean ± SD. (D and E) PK parameters for plasma
and brain were calculated using WinNonlin. n = 4 for each time point. AUClast, area under the curve concentration; Cmax, maximum plasma concentration;
HL_Lambda_z (days), half-life; Tmax (days), time to maximum plasma concentration. (F) Functional EC50 of AL002. Viability of primary hTREM2+ macrophages
from two distinct donors was measured by ATP assay after exposure of cells to different concentrations of AL002. The EC50 value of AL002 spans 0.36–0.47
nM (∼60 ng/ml).
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Figure S3. scRNA-seq of Cd45+ cells from brains of AL002c- and IgG-treated mice. (A) UMAP of all Cd45+ cells. Clusters were annotated using previously
identified gene markers: HM, homeostatic microglia; IRM, interferon-response microglia; NK, natural killer cells; CP BAM, choroid plexus BAMs. (B) Gene
expression heatmap for all Cd45+ clusters. Genes shown are the top gene markers for each cluster defined by a Wilcoxon rank-sum test. The number of cells
per cluster is denoted above the cluster label.
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Figure S4. Impact of AL002c treatment on total Aβ load. (A) Quantification of methoxy-X04+ area coverage in the cortex (Ctx) and hippocampus (HC) of
treated mice. Each CV-KO-5XFAD treatment group, n = 7; each R47H-KO-5XFAD treatment group, n = 6. (B) Volume of individual methoxy-X04+ Aβ plaques in
the cortex of indicated treatment groups. The volume of ∼1,000 plaques per condition was determined by Imaris. (C–F) PBS-soluble and PBS-insoluble
guanidine-soluble fractions of hippocampus were assessed for Aβ1–40 (C and E) and Aβ1–42 (D and F) by MSD. Values for PBS-soluble Aβ1–40 were below the
limit of detection in some samples. Each CV-KO-5XFAD treatment group, n = 7; each R47H-KO-5XFAD treatment group, n = 6. No differences were detected for
Aβ1–40 or Aβ1–42 in PBS-insoluble guanidine-soluble fractions of cortices among treatment groups (not depicted). PBS-soluble fractions of cortices showed no
detectable Aβ1–40 or Aβ1–42 by MSD. *, P < 0.05; **, P < 0.01 by two-way ANOVA. Data are presented as mean ± SEM.
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Figure S5. Impact of AL002c treatment on microglia clustering around plaques and Spp1 production (A) Representative confocal images from the
hippocampus of indicated groups of mice, showing Iba1+ microglia (green), TO-PRO3-stained nuclei (red), and methoxy-X04 labeled Aβ plaques (blue). Bar, 100
µm. (B and C) Quantification of Iba1+ area coverage in the cortex (Ctx) and hippocampus (HC) of treated mice (CV-KO-5XFAD, AL002c, n = 7; CV-KO-5XFAD,
IgG, n = 5; R47H-KO-5XFAD, AL002c, n = 6; R47H-KO-5XFAD, IgG, n = 6). Data are presented as mean ± SEM. (D) Representative confocal images from the
cortex of the indicated groups of mice, showing Iba1+ (green) microglia, TO-PRO3-stained nuclei (red), and methoxy-X04 labeled Aβ plaques (blue). Bar = 50
µm. CV-KO-5XFAD treatment group, n = 7; R47H-KO-5XFAD treatment group, n = 6. (E and F) Quantification of the density of microglia within a 15- or 30-µm
shell around plaque surfaces within cortex or hippocampus. The figure depicts one experiment representative of two biological replicates. *, P < 0.05 by two-
way ANOVA, showing significant difference for interaction between antibody treatment and genotype. Data are presented as mean ± SEM. (G) 5-mo-old
5XFAD and hTREM2-Bac-Tg × 5XFAD mice were injected i.p. with AL002c or IgG as control (n = 10) at 60 mg/kg weekly for 12 wk. Littermates were ad-
ministered the same concentration of IgG as a control group. SPP1 was measured by ELISA in brain lysates of treated mice. Each symbol represents data of one
mouse. ****, P < 0.0001 by one-way ANOVA. Data are presented as mean ± SEM.
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